americanpharmaceuticalreviewDecember 30, 2019
Tag: Seelos , Ketamine , SLS-002-102
Seelos Therapeutics announced the dosing of the first subjects in a Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) profile study, SLS-002-102.
SLS-002-102 is a two-part, randomized, double-blind, placebo-controlled, parallel and crossover study of intranasal and intravenous ketamine which plans to enroll 62 healthy volunteers.
"This study should help clarify SLS-002's safety and tolerability across multiple intranasal doses, as well help to identify and understand any pharmacokinetic or pharmacodynamic differences compared with IV ketamine. This information will assist us in confirming the dosing strategy for the planned proof of concept study in patients with MDD suffering from ASIB," said Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics.
Preliminary data from this study is expected in the first quarter of 2020.
Upon successful completion of the Phase I studies, Seelos plans to conduct a Proof of Concept (PoC) study of Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: